A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University Hospital Heidelberg
University of Hawaii
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
University of California, Davis
Emory University
M.D. Anderson Cancer Center
Baptist Health South Florida
University of Chicago
Emory University
Emory University
Alessa Therapeutics Inc.
Abramson Cancer Center at Penn Medicine
University of Maryland, Baltimore
Rutgers, The State University of New Jersey
Roswell Park Cancer Institute
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center